Revance’s board urges stockholders to vote in favor of Crown’s acquisition offer
Revance (RVNC) and Crown Laboratories reminded Revance stockholders of the recommendation to tender their shares in support of Crown’s cash ...
Revance Therapeutics set to go private with Crown Laboratories
Johnson City-based Crown Laboratories is now offering the public biotechnology company’s stockholders $3.65 per share of its ...
Teoxane Ends Revance Pursuit After Revised Crown Deal
Teoxane, which holds a 6.2% stake in Revance and is a key customer of the Nashville, Tenn., company, had proposed buying the rest of the company for $3.60 a share after Crown reduced its planned ...